15793-40-5
15793-40-5
Chemical Structure
Terodiline
- CAS No.: 15793-40-5
- Formula:C20H27N
- Molecular Weight:281.44
IUPAC Name: N-(tert-butyl)-4,4-diphenylbutan-2-amine
InChIKey: UISARWKNNNHPGI-UHFFFAOYSA-N
SMILES: CC(NC(C)(C)C)CC(C1=CC=CC=C1)C2=CC=CC=C2
Biological Activity: Terodiline, an antispasmodic agent, blocks hERG current with the IC50 of 375 nM. Terodiline has both anticholinergic and calcium antagonist properties, and effectively reduces abnormal bladder contractions caused by detrusor instability. Terodiline can be used for the research of urinary incontinence[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Terodiline | Terodiline, an antispasmodic agent, blocks hERG current with the IC50 of 375 nM. Terodiline has both anticholinergic and calcium antagonist properties, and effectively reduces abnormal bladder contractions caused by detrusor instability. Terodiline can be used for the research of urinary incontinence. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ruth L Martin, et al. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. J Cardiovasc Pharmacol. 2006 Nov;48(5):199-206. [Content Brief]
- [2]. H D Langtry, et al. Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence. Drugs. 1990 Nov;40(5):748-61. [Content Brief]
Keywords
